A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma

Gynecologic Oncology

Volumn 108, Issue 1, 2008, Pages 77-83

  Lachance, Jason A ^a   Stukenborg, George J ^a   Schneider, Bernard F ^a   Rice, Laurel W ^a   Jazaeri, Amir A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Brachytherapy; Cost effectiveness; Endometrial cancer; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA; BRACHYTHERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT;

EID: 37349004071     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.08.072     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 1 (Jan 2007) 43-66
2. Cardenes H., and Randall M.E. Clarity and confusion regarding adjuvant radiation therapy in early endometrial cancer. Gynecol Oncol 75 1 (Oct 1999) 1-3
3. Naumann R.W. The role of radiation therapy in early endometrial cancer. Curr Opin Obstet Gynecol 14 1 (Feb 2002) 75-79
4. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60 8 Suppl (Oct 15 1987) 2035-2041
5. Berman M.L. Adjuvant radiotherapy following properly staged endometrial cancer: what role?. Gynecol Oncol 92 3 (Mar 2004) 737-739
6. Greven K.M., D'Agostino Jr. R.B., Lanciano R.M., and Corn B.W. Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer?. Int J Radiat Oncol Biol Phys 42 1 (Aug 1 1998) 101-104
7. Irwin C., Levin W., Fyles A., Pintilie M., Manchul L., and Kirkbride P. The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage I disease. Gynecol Oncol 70 2 (Aug 1998) 247-254
8. MacLeod C., Fowler A., Duval P., D'Costa I., Dalrymple C., Elliott P., et al. Adjuvant high-dose rate brachytherapy with or without external beam radiotherapy post-hysterectomy for endometrial cancer. Int J Gynecol Cancer 9 3 (May 1999) 247-255
9. Randall M.E., Wilder J., Greven K., and Raben M. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys 19 1 (Jul 1990) 49-54
10. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 9213 (Apr 22 2000) 1404-1411
11. Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 3 (Mar 2004) 744-751
12. Orr Jr. J.W., Holimon J.L., and Orr P.F. Stage I corpus cancer: is teletherapy necessary?. Am J Obstet Gynecol 176 4 (Apr 1997) 777-788
13. Horowitz N.S., Peters III W.A., Smith M.R., Drescher C.W., Atwood M., and Mate T.P. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol 99 2 (Feb 2002) 235-240
14. MacLeod C., Fowler A., Duval P., D'Costa I., Dalrymple C., Firth I., et al. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer. Int J Radiat Oncol Biol Phys 42 5 (Dec 1 1998) 1033-1039
15. Ng T.Y., Perrin L.C., Nicklin J.L., Cheuk R., and Crandon A.J. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 79 3 (Dec 2000) 490-494
16. Petereit D.G., Tannehill S.P., Grosen E.A., Hartenbach E.M., and Schink J.C. Outpatient vaginal cuff brachytherapy for endometrial cancer. Int J Gynecol Cancer 9 6 (Nov 1999) 456-462
17. Alektiar K.M., Venkatraman E., Chi D.S., and Barakat R.R. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 62 1 (May 1 2005) 111-117
18. Naumann R.W., Higgins R.V., and Hall J.B. The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists. Gynecol Oncol 75 1 (Oct 1999) 4-9
19. Konski A., Sherman E., Krahn M., Bremner K., Beck J.R., Watkins-Bruner D., et al. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys 63 3 (Nov 1 2005) 788-794
20. Suh W.W., Hillner B.E., Pierce L.J., and Hayman J.A. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 61 4 (Mar 15 2005) 1054-1061
21. Rocconi R.P., Estes J.M., Leath III C.A., Kilgore L.C., Huh W.K., and Straughn Jr. J.M. Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis. Gynecol Oncol 97 2 (May 2005) 387-394
22. Inadomi J.M. Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol 16 6 (Jun 2004) 535-542
23. Barakat R.R., Goldman N.A., Patel D.A., Venkatraman E.S., and Curtin J.P. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 75 1 (Oct 1999) 99-102
24. Jhingran A., Burke T.W., and Eifel P.J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 56 5 (Aug 1 2003) 1366-1372
25. Michener C.M., Peterson G., Kulp B., Webster K.D., and Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol 131 9 (Sep 2005) 581-584
26. Einbinder J.S., and Scully K. Using a clinical data repository to estimate the frequency and costs of adverse drug events. Proc AMIA Symp (2001) 154-158
27. Einbinder J.S., Scully K.W., Pates R.D., Schubart J.R., and Reynolds R.E. Case study: a data warehouse for an academic medical center. J Healthc Inf Manag 15 2 (2001) 165-175
28. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 51 5 (Dec 1 2001) 1246-1255
29. Pearcey R.G., and Petereit D.G. Post-operative high dose rate brachytherapy in patients with low to intermediate risk endometrial cancer. Radiother Oncol 56 1 (Jul 2000) 17-22
30. Naumann R.W., and Coleman R.L. The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005. Gynecol Oncol 105 1 (Apr 2007) 7-12
31. Ashih H., Gustilo-Ashby T., Myers E.R., Andrews J., Clarke-Pearson D.L., Berry D., et al. Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol 74 2 (Aug 1999) 208-216
32. Barnes M.N., Roland P.Y., Straughn M., Kilgore L.C., Alvarez R.D., and Partridge E.E. A comparison of treatment strategies for endometrial adenocarcinoma: analysis of financial impact. Gynecol Oncol 74 3 (Sep 1999) 443-447
33. Fanning J., Hoffman M.L., Andrews S.J., Harrah A.W., and Feldmeier J.J. Cost-effectiveness analysis of the treatment for intermediate risk endometrial cancer: postoperative brachytherapy vs. observation. Gynecol Oncol 93 3 (Jun 2004) 632-636